PepGen Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- PepGen Inc. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company founded in 2018 and headquartered at 321 Harrison Avenue, Boston, Massachusetts, develops next-generation oligonucleotide therapeutics leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to address severe neuromuscular and neurological diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The company's lead candidates include PGN-EDODM1, an EDO peptide-conjugated phosphorodiamidate morpholino oligomer (PMO) in Phase 2 trials (FREEDOM2-DM1, recruiting; FREEDOM-DM1, enrollment completed) targeting splicing correction in DM1 patients aged 16-60; PGN-EDO51 in Phase 2 for exon 51-skipping amenable DMD patients; and PGN-EDO53 in preclinical development for DMD, with the EDO technology engineered for improved tissue penetration, cellular uptake, and nuclear delivery across muscle types and the central nervous system. PepGen operates primarily in the United States, focusing on rare genetic disorders with high unmet needs through its pipeline of disease-modifying therapies; it also supports custom oligonucleotide synthesis, preclinical development services including PK/PD studies and toxicology, and expertise in peptide-drug conjugates for blood-brain barrier crossing. In September 2025, PepGen closed a $115 million underwritten public offering of common stock priced at $3.20 per share, including the full exercise of underwriters' option for additional shares led by Leerink Partners and Stifel, with net proceeds funding ongoing clinical trials such as FREEDOM-DM1 and FREEDOM2-DM1, research expansion, working capital, and general corporate purposes; the company continues to advance discovery programs in additional neuromuscular and neurological indications while maintaining approximately 81 employees and leadership under President and CEO James McArthur.
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG